REBECCA VELA: Open Payments
NPI 1629497334 · CHARLOTTE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$958 in 39 payments from 15 companies in 2025. Trend: 2023 $2,302 · 2024 $2,430 · 2025 $958
Food & beverage: $958
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $192 |
| ABBVIE INC. | 7 | $167 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $116 |
| Merck Sharp & Dohme LLC | 3 | $92 |
| Alexion Pharmaceuticals, Inc. | 3 | $80 |
| PFIZER INC. | 4 | $73 |
| SCPHARMACEUTICALS INC. | 1 | $41 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 2 | $37 |
| Novartis Pharmaceuticals Corporation | 1 | $33 |
| Gilead Sciences, Inc. | 1 | $30 |
Products named: JARDIANCE, XIFAXAN, ZERBAXA, ULTOMIRIS, ELIQUIS, TEFLARO, UBRELVY, FUROSCIX.
Industry payments across NC — which companies pay providers there.
